Sam Brusco, Associate Editor03.21.23
AdvaMed has named Ashley McEvoy, executive VP and worldwide chairman of medtech at Johnson & Johnson, as its new chairman for a two-year term, beginning March 21.
McEvoy has served on AdvaMed’s board since 2018, leading important initiatives for the association. She oversaw AdvaMed’s efforts to expand and fortify global market access for U.S. medtech firms through leading the International Board Committee. She helped work to restore elective procedures during the pandemic, and led the board’s efforts to address healthcare and outcome disparities in reflected in the association’s Principles on Health Equity.
McEvoy leads J&J’s $27 billion medtech business. She succeeds Abiomed’s former chairman, president, and CEO Michael Minogue.
She was also recently honored as one of 50 people named to Forbes’ inaugural CEO NEXT list and was ranked #1 on the Top 25 Women Leaders in Medical Devices list by The Healthcare Technology Report. She ranked #41 on Fortune’s Most Powerful Women List in 2019 and was named a Woman of Achievement in 2020 by the National Association of Female Executives for her dedication to advancing diversity, equity, and inclusion.
McEvoy said to the press: “It’s an exciting time for the medtech industry, and I’m honored and grateful for the opportunity to serve as Chair of the AdvaMed Board of Directors. I’ve seen the impact AdvaMed has had on advancing policies that improve patient access to safe, effective, and innovative medical technologies and know we will continue to advance that mission. As Chair, I will build on the work of my predecessors to imagine new ways to improve patient health and elevate the standard of care through innovation, industry growth, and improved access for the patients we serve.”
McEvoy shared with the Board her primary areas of focus during her upcoming two-year term. In addition to supporting AdvaMed’s Innovation Agenda to improve patient access to innovative new medical technologies, McEvoy said she will work with the Board and AdvaMed membership to:
AdvaMed president and CEO Scott Whitaker said of McEvoy: “Ashley McEvoy’s leadership across her long career in medtech and as a member of AdvaMed’s Board has prepared her well to lead the medtech industry as Board Chair. Her focus on helping to build a more resilient healthcare system, driving digital transformation, and making an impact for patients will help set our industry on the right path following the challenges of the pandemic. I know I speak for the entire Board when I say we look forward to a bright future for AdvaMed and the industry with Ashley at the helm. I look forward to working with her and the Board to help our companies to continue doing what they do best—improving and saving patients’ lives.”
McEvoy has served on AdvaMed’s board since 2018, leading important initiatives for the association. She oversaw AdvaMed’s efforts to expand and fortify global market access for U.S. medtech firms through leading the International Board Committee. She helped work to restore elective procedures during the pandemic, and led the board’s efforts to address healthcare and outcome disparities in reflected in the association’s Principles on Health Equity.
McEvoy leads J&J’s $27 billion medtech business. She succeeds Abiomed’s former chairman, president, and CEO Michael Minogue.
She was also recently honored as one of 50 people named to Forbes’ inaugural CEO NEXT list and was ranked #1 on the Top 25 Women Leaders in Medical Devices list by The Healthcare Technology Report. She ranked #41 on Fortune’s Most Powerful Women List in 2019 and was named a Woman of Achievement in 2020 by the National Association of Female Executives for her dedication to advancing diversity, equity, and inclusion.
McEvoy said to the press: “It’s an exciting time for the medtech industry, and I’m honored and grateful for the opportunity to serve as Chair of the AdvaMed Board of Directors. I’ve seen the impact AdvaMed has had on advancing policies that improve patient access to safe, effective, and innovative medical technologies and know we will continue to advance that mission. As Chair, I will build on the work of my predecessors to imagine new ways to improve patient health and elevate the standard of care through innovation, industry growth, and improved access for the patients we serve.”
McEvoy shared with the Board her primary areas of focus during her upcoming two-year term. In addition to supporting AdvaMed’s Innovation Agenda to improve patient access to innovative new medical technologies, McEvoy said she will work with the Board and AdvaMed membership to:
- Build a more resilient healthcare system through policy enhancement and improved supply chain operations
- Drive digital transformation in medtech through ethical policies that promote the responsible use of data
- Ensure the medtech industry reflects the patients it serves through programs that increase diverse representation and continue to improve diversity in clinical research
AdvaMed president and CEO Scott Whitaker said of McEvoy: “Ashley McEvoy’s leadership across her long career in medtech and as a member of AdvaMed’s Board has prepared her well to lead the medtech industry as Board Chair. Her focus on helping to build a more resilient healthcare system, driving digital transformation, and making an impact for patients will help set our industry on the right path following the challenges of the pandemic. I know I speak for the entire Board when I say we look forward to a bright future for AdvaMed and the industry with Ashley at the helm. I look forward to working with her and the Board to help our companies to continue doing what they do best—improving and saving patients’ lives.”
